MEDIANTECHNOLOGIES news, videos and press releases
For more news please use our advanced search feature.
MEDIANTECHNOLOGIES - More news...
MEDIANTECHNOLOGIES - More news...
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of March 31, 2025
- eyonis™ LCS, Median Technologies’ AI-Powered Software as a Medical Device for Lung Cancer Screening, Confirmed Efficacy and Safety in RELIVE Pivotal Study
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of February 28, 2025
- Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Extraordinary General Meeting on March 20, 2025
- Median Technologies to Present at TD Cowen’s 45th Annual Health Care Conference
- Median Technologies to Showcase Its Artificial Intelligence Software as a Medical Device for Lung Cancer Screening, eyonis™ LCS, at the European Congress of Radiology
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of January 31st, 2025
- Median Technologies Gives Update on Drawdowns of the Iris Equity Line
- Median Technologies: eyonis™ Lung Cancer Screening (LCS) Meets Primary Endpoint in RELIVE Clinical Trial, the Final Pivotal Study Required for Regulatory Submissions
- Median Technologies Reports 2024 Key Financial Indicators and 2025 Outlook
- Median Technologies securing up to €47.5 million to support AI lung cancer diagnostic eyonis™ regulatory filings and commercialization in U.S. and EU
- Median Technologies: Financial Communications Schedule for the First Half of 2025
- Half Year Median Technologies Liquidity Contract Statement
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of December 31st, 2024
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of November 30th, 2024
- Median Technologies to Showcase AI-Powered Lung Cancer Diagnostic eyonis™ LCS at the Radiological Society of North America (RSNA) 2024
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of October 31st, 2024
- Median Technologies Reports 2023 Revenue and Summarizes 2024 Strategic Outlook
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of July 31st, 2023
- Median Technologies: Financial Communication Schedule for the Second Half of 2023
- Portzamparc Groupe BNP Paribas Initiates the Coverage of Median Technologies with a “Strong Buy” Recommendation
- Median Technologies to Host Two Webcasts and Provide a Company Update on July 20, 2023
- Median Technologies Announces Onboarding of All Academic Sites Involved in the Pivotal Validation Plan for iBiopsy® LCS CADe/CADx SaMD
- Median Technologies announces successful EUR 11.6 million capital increase through a private placement and a public offering at a subscription price of €4.70 per share
- Median Technologies Announces Launch of a Capital Increase Through a Private Placement and a Public Offering
- Median Technologies Reports Its Business Activity for the First Half of 2023 and Announces the First Step of Its Refinancing Plan
- Half Year Median Technologies Liquidity Contract Statement Contracted With TP ICAP
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of June 30th, 2023
- Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31st, 2023
- Median Technologies to participate in the 2023 ASCO Annual Meeting, June 2-6, 2023, McCormick Place, Chicago, IL, USA
